RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals plc) is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. We are currently commercializing Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelids, in adults. Upneeq is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
August 23, 2023
August 16, 2023
August 14, 2023
Events and Presentations
Oct 2, 2023 at 10:00 AM EDT
More information is coming soon.